Reviva Pharmaceuticals Holdings provided program updates and announced upcoming key milestones. “In 2023, we made significant progress across our late-stage brilaroxazine clinical program in schizophrenia, including positive topline Phase 3 data demonstrating statistically significant reductions across all major symptom domains, successful ongoing enrollment in our one-year OLE trial, and positive clinical drug-drug interaction data supporting a competitive profile for once-daily brilaroxazine,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. Anticipated Milestones and Events: Topline data from 1-year OLE trial expected Q4 2024; Initiation of registrational Phase 3 RECOVER-2 trial expected Q1 2024; Initiation of investigational new drug application enabling studies for liposomal-gel formulation of brilaroxazine in psoriasis expected in 2024; May initiate Phase 2 studies in bipolar disorder, major depressive disorder, and attention deficit hyperactive disorder in 2024; Pursue partnership opportunities for the development of our pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVPH:
- Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
- Reviva may be most undervalued in neurology, says H.C. Wainwright
- Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
- Largest borrow rate increases among liquid names
